Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

"Kevetrin patent expires September 2030. That's just over 9 years from now. Kevetrin has 4-5 years of clinical trial development and NDA time if it passes with flying colors. So assuming we start this year that leaves only 4-5 years of revenue. What are the odds we restart Kevetrin trials this year or next?"

Exactly. Couple that with why has Beth Israel (the first k trial site), MD Anderson, and the Dartmouth affiliated hospital seemingly not promoted K? Why give the inventor of K the pink slip if it has so much potential.

Why, apparently, has no one been knocking on the door, nor ringing the bell about K after a spectacular phase 2 study comprising 2 patients?